Ferring Pharmaceuticals Launches $500M Gene Therapy Facility in New Jersey.

New 12,000-sq-ft NJ facility produces groundbreaking gene therapy for NMIBC, marking $1B+ investment in innovative oncology treatment.

New 12,000-Sq-Ft Plant to Produce FDA-Approved Bladder Cancer Treatment ADSTILADRIN

Key Highlights

✔ Location: Parsippany, New Jersey (US headquarters)
✔ Investment: $500M+ in manufacturing (part of $1B+ total R&D spend)
✔ Product Focus: ADSTILADRIN – First FDA-approved bladder-targeted gene therapy
✔ Capacity: Dedicated production for high-risk non-muscle-invasive bladder cancer (NMIBC)


Strategic Significance

1. Breakthrough Therapy Production

  • ADSTILADRIN is a non-replicating adenoviral vector therapy
  • Single-dose treatment delivered via catheter directly to bladder
  • Clinical benefits: 51% complete response rate in CIS+Ta/T1 patients (Phase 3 trial)

2. Manufacturing Excellence

🧪 Advanced Bioprocessing:

  • Cell culture, viral vector production, purification
  • Strict FDA cGMP compliance

📦 Supply Chain Control:

  • End-to-end production under one roof
  • Ensures therapy accessibility for US patients

3. Economic & Medical Impact

💊 Addresses Unmet Need:

  • ~80,000 NMIBC cases annually in US
  • Alternative to repeat BCG immunotherapy failures

💼 New Jersey Biotech Boost:

  • Strengthens state’s “Medicine Chest of the World” status
  • Creates high-skilled biopharma jobs

Leadership Perspectives

Brent Ragans, US President, Ferring:
“This facility embodies our commitment to transformative gene therapies. ADSTILADRIN offers new hope for bladder cancer patients who’ve exhausted other options.”

Jean-Frédéric Paulsen, Chairman:
*”A decade and $1B investment culminates today. We’re proud to deliver this first-of-its-kind treatment from our NJ home.”*

Fran (Patient Advocate):
“As someone who battled NMIBC, I know how desperately this therapy is needed. Today gives patients like me real hope.”


Technical Specifications

🏭 Facility Size: 12,000 sq ft
🔬 Cleanrooms: BSL-2 compliant
📅 Development Timeline: 10+ years from discovery to FDA approval (2022)


Market Context

💰 ADSTILADRIN Pricing: ~$157,000 per dose
🌎 Global Expansion Plans: EMA approval pending
🔍 Pipeline Potential: Platform for additional gene therapies


Ceremony Attendees

  • Government:
    • Rep. Mikie Sherrill’s office
    • NJ State Sen. Joe Pennacchio
    • Parsippany Mayor James Barberio
  • Industry:
    • Ferring’s global tech ops leadership
  • Patient Advocates:
    • Bladder Cancer Advocacy Network

Scroll to Top